InflaRx (IFRX) Treasury Shares (2016 - 2018)
InflaRx's (IFRX) quarterly Treasury Shares came in at -$57069.8 in Q4 2018, down 115.1% quarter-over-quarter from $377903.5 in Q4 2016.
Powered by 
Analysis
InflaRx (IFRX) Treasury Shares (2016 - 2018) Analysis & Trends
InflaRx has disclosed Treasury Shares across 2 years of filings, most recently posting -$57069.8 for Q4 2018.
- In Q4 2018, Treasury Shares changed N/A year-over-year to -$57069.8; the TTM figure through Dec 2018 stood at -$57069.8 (changed N/A YoY), while the FY2018 annual figure was -$59066.5, changed N/A from the prior year.
- Treasury Shares came in at -$57069.8 for Q4 2018 at InflaRx, down from $377903.5 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $377903.5 in Q4 2016 to a low of -$57069.8 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 36.40 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.80 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | -57,069.82 |
| Dec 31, 2018 | -57,069.82 |
| Dec 31, 2016 | 377,903.48 |
| Dec 31, 2016 | 377,903.48 |